Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
TipRanksMay 2 14:16
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63
MT NewswiresMay 1 22:20
Truist Securities: Reiterates Incyte's (INCY.US) rating and adjusted from buy to buy rating, target price adjusted from $84.00 to $83.00.
Zhitong FinanceMay 1 20:50
Truist Securities Reiterates Buy on Incyte, Lowers Price Target to $83
BenzingaMay 1 20:47
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
TipRanksMay 1 20:01
Incyte Analyst Ratings
BenzingaMay 1 20:00
BMO Capital Adjusts Incyte Price Target to $52 From $56
MT NewswiresMay 1 19:50
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
TipRanksMay 1 18:39
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
TipRanksMay 1 12:40
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained
MT NewswiresMay 1 02:57
Incyte's Strategic Acquisition and Promising Pipeline Secure Buy Rating
TipRanksApr 26 14:16
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
TipRanksApr 24 19:46
Incyte Analyst Ratings
BenzingaApr 24 19:21
Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84
BenzingaApr 24 19:22
Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation
TipRanksApr 24 17:35
Incyte (INCY) Gets a Buy From Piper Sandler
TipRanksApr 24 03:25
Incyte Analyst Ratings
BenzingaApr 23 19:59
Incyte (INCY.US) was first covered by Cantor Fitzgerald, giving it a neutral rating.
Zhitong FinanceApr 23 20:01
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)
TipRanksApr 9 10:40
Incyte Analyst Ratings
BenzingaMar 25 22:25
No Data
No Data